We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results:1-10 of 174

President Trump Signs Bipartisan Opioid Legislation into Law; Includes Open Payments Reporting Expansion
  • Reed Smith LLP
  • USA
  • October 24 2018

President Trump has just signed into law HR 6, the Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment (SUPPORT) for


Trump Administration Highlights Regulatory and Deregulatory Priorities for HHS
  • Reed Smith LLP
  • USA
  • October 18 2018

As part of the Trump Administration’s fall regulatory agenda, the Department of Health and Human Services (HHS) emphasizes its commitment to “reducing


Federal Health Fraud Penalties Are Rising Once Again
  • Reed Smith LLP
  • USA
  • October 11 2018

The Department of Health and Human Services (HHS) has just announced annual inflation-related increases to civil monetary penalties (CMPs) in its


House Approves Sweeping Opioid PreventionTreatment Legislation
  • Reed Smith LLP
  • USA
  • July 5 2018

The House of Representatives has overwhelmingly approved bipartisan legislation, HR 6, the SUPPORT for Patients and Communities Act, intended to


New CMS Guidance for ADLT Lab Tests and ADLT Application Released
  • Reed Smith LLP
  • USA
  • April 6 2018

CMS is still rolling out policies and procedures to fully implement the major clinical laboratory payment reforms mandated by the Protecting Access to


House Panel Approves Off-Label Communication, OTC Monograph User Fee, Good Samaritan Health Professionals Bills
  • Reed Smith LLP
  • USA
  • January 23 2018

The House Energy and Commerce Health Subcommittee voted to approve the following health policy bills on January 18, 2017...


OIG Report Assesses Accuracy of Manufacturer-Reported Medicaid Rebate Program Data
  • Reed Smith LLP
  • USA
  • December 21 2017

The OIG recently issued a report evaluating the accuracy of pharmaceutical manufacturer-reported Medicaid drug rebate program data, including pricing


Congressional Hearings Focus on Health Policy Issues
  • Reed Smith LLP
  • USA
  • November 29 2017

A number of Congressional panels have scheduled or held recent hearings on health policy issues, including the following...


OIG Wants CMS to Track Medicare Costs from Device Failures
  • Reed Smith LLP
  • USA
  • October 27 2017

A recent Office of Inspector General (OIG) report suggests that the lack of medical device-specific information on Medicare claim forms complicates


OIG Targets Additional MedicareMedicaid Policy Areas for Review
  • Reed Smith LLP
  • USA
  • June 15 2017

The OIG has added 18 reviews to its FY 2017 Work Plan - most of which target CMS programs, with a particular emphasis on prescription drug policies